EGF application is able to enhance VEGF-A production and to induce PI3K-dependent positive feedback on AKT and ERK via VEGFR2 in hematological malignancies (human monocytic leukemia THP1 cell line and Burkitt’s lymphoma Raji cell line (Saryeddine et al., 2016). This evidence concerns the gene AKT1 and monocytic leukemia.